The Закавказ Heal βελτι story revealed resilient results amid challenging economic times. Skin care, consumer health, and pharmaceuticals segments performed well, while medical devices faced generic competition and Cordis business decline. The robust pipeline and promising late-stage pharmaceuticals offsets short-term pressures. The balanced approach to business and focus on emerging markets is commendable. The stock is likely to witness a mild positive momentum in the short term.

1